Pharmaceutical - palbociclib

Filter

Current filters:

palbociclib

Popular Filters

Pfizer to submit NDA for breast cancer drug palbociclib later this year

18-05-2014

US pharma giant Pfizer says that it will submit a New Drug Application with the US Food and Drug Administration…

OncologypalbociclibPfizerPharmaceuticalRegulationUSA

Pfizer palbociclib trial disappoints, despite meeting primary endpoint

Pfizer palbociclib trial disappoints, despite meeting primary endpoint

08-04-2014

At the American Association of Cancer Research (AACR) Annual Meeting 2014 in San Diego, US pharma giant…

AmgenOncologypalbociclibPfizerPharmaceuticalResearch

Strong mid-stage trial results for Pfizer’s palbociclib in advanced breast cancer

Strong mid-stage trial results for Pfizer’s palbociclib in advanced breast cancer

03-02-2014

Positive results from a randomized Phase II trial [PALOMA-1] of US pharma giant Pfizer’s palbociclib…

OncologypalbociclibPfizerPharmaceuticalResearch

Pfizer and GSK link up to trial combo melanoma therapy

Pfizer and GSK link up to trial combo melanoma therapy

22-11-2013

Two of the world’s pharma giants, USA-based Pfizer and the UK’s GlaxoSmithKline have joined forces…

GlaxoSmithKlineMekinistOncologypalbociclibPfizerPharmaceuticalResearchtrametinib

Breakthrough status for Pfizer's palbociclib; Merck & Co Noxafil NDA accepted

11-04-2013

Global pharma behemoth Pfizer (NYSE: PFE) is the latest to gain a "Breakthrough Therapy" designation…

Antibiotics and Infectious diseasesMerck & CoNorth AmericaNoxafilOncologypalbociclibPfizerPharmaceuticalRegulation

Back to top